Advertisement

Drugs & Therapy Perspectives

, Volume 34, Issue 7, pp 350–350 | Cite as

Correction to: Olmesartan medoxomil/amlodipine/hydrochlorothiazide 20 mg/5 mg/12.5 mg fixed-dose combination in hypertension: a profile of its use

  • Katherine A. Lyseng-Williamson
Correction
  • 370 Downloads

Correction to: Drugs Ther Perspect. 2018;34(1):1–7  https://doi.org/10.1007/s40267-017-0465-z

Page 2, column 2, section “What is the clinical efficacy of OLM/AMT/HCT 20 mg/5 mg/12.5 mg?”, paragraph 1, lines 5–8: The following text, which previously read:

“this section focuses primarily on results in patients who received the relatively low-dose combination of OLM 20 mg + AML 10 mg + HCT 12.5 mg”.

Should read:

“this section focuses primarily on results in patients who received the relatively low-dose combination of OLM 20 mg + AML 5 mg + HCT 12.5 mg.”

Page 5, column 1, subsection “Blood pressure control”, paragraph 1, lines 1–3: the following text, which previously read:

“Across all dosages, OLM/AML/HCT improved DBP and SBP from baseline by a mean of − 28.8 and − 13.9 mmHg, respectively, at study end”

Should read:

“Across all dosages, OLM/AML/HCT improved SBP and DBP from baseline by a mean of − 28.8 and − 13.9 mmHg, respectively, at study end”

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  1. 1.SpringerAucklandNew Zealand

Personalised recommendations